MULTIPLE MYELOMA

The CARTITUDE-4 study found that cilta-cel reduced the risk of death by 45% compared to standard of care in patients with multiple myeloma.

Ashraf Z. Badros, MB, ChB, discusses the key takeaways from the phase 3 AURIGA trial.

A study found that anito-cel is a promising CAR T-cell therapy for relapsed/refractory multiple myeloma with high efficacy and manageable safety.

A new CAR T-cell therapy, durcabtagene autoleucel, showed promising results in treating relapsed/refractory multiple myeloma with high response rates and manageable adverse effects.

Daratumumab plus VRd is a more effective frontline treatment option for patients who cannot undergo immediate transplant, offering a promising approach to deeper disease response.

Maintenance therapy with daratumumab and lenalidomide led to higher MRD-negative conversion rates compared to lenalidomide alone in newly diagnosed multiple myeloma patients following transplant.

Isa-KRd showed deep responses, high MRD negativity rates, and manageable safety in patients with newly diagnosed, transplant-eligible multiple myeloma, as per interim analysis of the IFM2020-02 MIDAS study.

In TRIMM-2, an overall response rate of 82% was seen amon patients given talquetamab plus daratumumab and pomalidomide in patients with relapsed/refractory multiple myeloma.

Binod Dhakal, MD, MS, discusses some of the challenges often seen in the myeloma space, particularly those with lenalidomide-refractory multiple myeloma.

A new drug combination, talquetamab and teclistamab, shows promising results in treating patients with heavily pretreated multiple myeloma, with high response rates and durable responses.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the phase 3 CEPHEUS trial of daratumumab with bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

During a Case-Based Roundtable® event, Samer A. Al'Hadidi, MD, MS, discussed the CARTITUDE-4 trial of cilta-cel in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series.

Hamlet Gasoyan, MD, discusses what to know from a study that found there to be disparities in time to treatment with oral antimyeloma medications when used in patients with newly diagnosed multiple myeloma.

The approval is supported by data from the phase 3 IMROZ study which demonstrated superior progression-free survival with isatuximab plus VRd vs VRd alone in patients with newly diagnosed, transplant-ineligible multiple myeloma.

During a Case-Based Roundtable® event, Ajay Nooka, MD, MPH, discussed adverse events related to talquetamab for multiple myeloma and explored research into outpatient treatment with teclistamab, another bispecific T-cell engager.

During a Case-Based Roundtable® event, Andrzej Jakubowiak, MD, PhD, discussed 2 recent trials in multiple myeloma for isatuximab combination treatment in the first article of a 2-part series.

Following promising preliminary findings from a phase 1 study, the FDA granted P-BCMA-ALLO1 regenerative medicine advanced therapy designation in relapsed/refractory multiple myeloma.

During a Case-Based Roundtable® event, Tara K. Gregory, MD, discussed how to implement use of bispecific T-cell engagers in patients with relapsed/refractory multiple myeloma in the second article of a 2-part series.

Updated findings from the PERSEUS study found that patients with newly diagnosed multiple myeloma benefited from a treatment regimen involving daratumumab, bortezomib, lenalidomide, and dexamethasone before and after autologous stem cell transplant.

The ready-to-use formulation of bortezomib is now an FDA-approved option for patients with multiple myeloma and mantle cell lymphoma.

During a Case-Based Roundtable® event, Tara K. Gregory, MD, discussed the MonumenTAL-1 trial of talquetamab in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series.

The FDA issued a complete response letter for linvoseltamab aimed at treating relapsed/refractory multiple myeloma post multiple therapies.

During a Case-Based Roundtable® event, Rafat Abonour, MD, moderated a peer discussion on the use of bispecific T-cell engagers in patients with relapsed/refractory multiple myeloma.

In an interview, Amrita Krishnan, MD, discussed several key advancements and challenges in the field of multiple myeloma.

In an interview, Marc Braunstein, MD, PhD, reviewed key updates in multiple myeloma for chimeric antigen receptor (CAR) T-cell and bispecific antibody therapy, and discussed planning for transition of care.

Isatuximab plus VRd induction before transplant led to better progression-free survival compared with VRd alone, according to data from the GMMG-HD7 phase 3 study.

During a Case-Based Roundtable® event, Andrew Yee, MD, discussed myeloma treatment strategies for different age groups, focusing on personalized regimens and the pros and cons of CAR T-cell therapy and bispecific antibodies in the second article of a 2-part series.

Taiga Nishihori, MD, discusses the findings from a study evaluating ciltacabtagene autoleucel given in the outpatient setting to patients with relapsed/refractory multiple myeloma.

Paula Rodríguez Otero, MD, PhD, discussed the findings from the minimal residual disease analysis of the PERSEUS study.

Findings from the phase 3 PERSEUS study support the approval of subcutaneous daratumumab and bortezomib, lenalidomide, and dexamethasone in this patient population.